APA (7th ed.) Citation

Kuboki, Y., Pietrantonio, F., Salvatore, L., Meriggi, F., Modest, D., Yaeger, R., . . . Hong, D. (2025). 743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). Annals of Oncology, 36, S518. https://doi.org/10.1016/j.annonc.2025.08.1317

Chicago Style (17th ed.) Citation

Kuboki, Y., et al. "743P Combined Analysis of Overall Survival (OS) from the Phase III CodeBreaK 300 and Phase Ib CodeBreaK 101 Studies of Sotorasib 960 Mg Plus Panitumumab (soto960+pani) Therapy for Chemorefractory KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)." Annals of Oncology 36 (2025): S518. https://doi.org/10.1016/j.annonc.2025.08.1317.

MLA (9th ed.) Citation

Kuboki, Y., et al. "743P Combined Analysis of Overall Survival (OS) from the Phase III CodeBreaK 300 and Phase Ib CodeBreaK 101 Studies of Sotorasib 960 Mg Plus Panitumumab (soto960+pani) Therapy for Chemorefractory KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)." Annals of Oncology, vol. 36, 2025, p. S518, https://doi.org/10.1016/j.annonc.2025.08.1317.